Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study / Justine M. KENT in Journal of Autism and Developmental Disorders, 43-8 (August 2013)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 43-8 (August 2013) . - p.1773-1783 Titre : Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study Type de document : texte imprimé Auteurs : Justine M. KENT, Auteur ; Stuart KUSHNER, Auteur ; Xiaoping NING, Auteur ; Keith KARCHER, Auteur ; Seth NESS, Auteur ; Michael G. AMAN, Auteur ; Jaskaran SINGH, Auteur ; David HOUGH, Auteur Article en page(s) : p.1773-1783 Langues : Anglais (eng) Mots-clés : Autistic disorder  Double-blind  Placebo-controlled  Risperidone Index. décimale : PER Périodiques Résumé : Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5–17 years), received risperidone (low-dose: 0.125 mg/day [20 to 45 kg], 0.175 mg/day [45 kg] or high-dose: 1.25 mg/day [20 to 45 kg], 1.75 mg/day [45 kg]) or placebo. Mean baseline (range 27–29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose—(−12.4 [6.5]; p 0.001), but not low-dose (−7.4 [8.1]; p = 0.164) group, versus placebo (−3.5 [10.7]). Clinical Global Impressions-Severity and Children’s Yale-Brown Obsessive Compulsive Scale scores improved significantly only in the high-dose group, consistent with ABC-I results. Somnolence, sedation and increased appetite occurred more frequently in high-versus low-dose groups. Overall, increased appetite occurred most frequently. En ligne : http://dx.doi.org/10.1007/s10803-012-1723-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=205 [article] Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study [texte imprimé] / Justine M. KENT, Auteur ; Stuart KUSHNER, Auteur ; Xiaoping NING, Auteur ; Keith KARCHER, Auteur ; Seth NESS, Auteur ; Michael G. AMAN, Auteur ; Jaskaran SINGH, Auteur ; David HOUGH, Auteur . - p.1773-1783. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 43-8 (August 2013) . - p.1773-1783 Mots-clés : Autistic disorder  Double-blind  Placebo-controlled  Risperidone Index. décimale : PER Périodiques Résumé : Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5–17 years), received risperidone (low-dose: 0.125 mg/day [20 to 45 kg], 0.175 mg/day [45 kg] or high-dose: 1.25 mg/day [20 to 45 kg], 1.75 mg/day [45 kg]) or placebo. Mean baseline (range 27–29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose—(−12.4 [6.5]; p 0.001), but not low-dose (−7.4 [8.1]; p = 0.164) group, versus placebo (−3.5 [10.7]). Clinical Global Impressions-Severity and Children’s Yale-Brown Obsessive Compulsive Scale scores improved significantly only in the high-dose group, consistent with ABC-I results. Somnolence, sedation and increased appetite occurred more frequently in high-versus low-dose groups. Overall, increased appetite occurred most frequently. En ligne : http://dx.doi.org/10.1007/s10803-012-1723-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=205

---

1 (1 - 1 / 1) Par page : 25 50 100 200